Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VRDN advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where VRDN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on January 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRDN as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for VRDN turned negative on February 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
VRDN moved below its 50-day moving average on February 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRDN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
VRDN broke above its upper Bollinger Band on January 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VRDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.690) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (36.630) is also within normal values, averaging (331.843).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of biopharmaceuticals
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| USPFX | 34.80 | 0.19 | +0.55% |
| Union Street Partners Value Advisor | |||
| GSCIX | 46.89 | 0.22 | +0.47% |
| abrdn US Small Cap Equity Inst | |||
| IRGFX | 23.51 | -0.09 | -0.38% |
| Nomura Small Cap Growth R6 | |||
| AFDRX | 47.08 | -0.57 | -1.20% |
| American Century Large Cap Equity R | |||
| VHCAX | 226.72 | -3.39 | -1.47% |
| Vanguard Capital Opportunity Adm | |||
A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with SYRE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To VRDN | 1D Price Change % | ||
|---|---|---|---|---|
| VRDN | 100% | -3.92% | ||
| SYRE - VRDN | 57% Loosely correlated | +1.65% | ||
| NUVL - VRDN | 57% Loosely correlated | +2.12% | ||
| OCUL - VRDN | 52% Loosely correlated | -6.99% | ||
| AGIO - VRDN | 52% Loosely correlated | -0.82% | ||
| CRNX - VRDN | 52% Loosely correlated | +1.24% | ||
More | ||||